Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis
ISRCTN | ISRCTN14200211 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN14200211 |
Secondary identifying numbers | vit K 2006 |
- Submission date
- 02/04/2008
- Registration date
- 09/05/2008
- Last edited
- 27/04/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Lieske Kuitert
Scientific
Scientific
Department of Respiratory Medicine
London Chest Hospital
Bonner Road
London
E2 9JX
United Kingdom
Study information
Study design | Randomised double-blind placebo-controlled study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Investigating the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis |
Study objectives | Vitamin K supplementation improves markers of bone turnover and bone density in adolescents and adults with cystic fibrosis (CF). |
Ethics approval(s) | Wandsworth Research Ethics Committee, 11/08/2006 (protocol v4), 18/05/2007 (amendments protocol v5) and 03/08/2007 (amendments protocol v6). |
Health condition(s) or problem(s) studied | Bone health in cystic fibrosis |
Intervention | 1. 10 mg of menadiol phosphate (water soluble form of vitamin K) once daily (o.d.) orally for 12 months 2. Matching placebo for 12 months Total duration of treatment and follow-up: 12 months for both arms. |
Intervention type | Supplement |
Primary outcome measure | The between-groups difference in the ratio of undercarboxylated osteocalcin to total osteocalcin, measured prior to supplementation starting and at the end of the 12 months supplementation. |
Secondary outcome measures | The between-group differences in: 1. Total osteocalcin 2. Undercarboxylated osteocalcin 3. N Terminal X (marker of bone resorption) 4. Bone specific alkaline phosphatase 5. Serum vitamin D 6. Calcium 7. Dual energy x-ray absorptiometry (DEXA) scan z and t scores of lumbar spine and femoral neck (scores adjusted for age, height and sex) Measured prior to supplementation starting and at the end of the 12 months supplementation. |
Overall study start date | 02/01/2007 |
Completion date | 09/02/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 40 |
Key inclusion criteria | 1. Patients with a diagnosis of CF (positive sweat test or genotype testing) 2. Patients aged greater than 16 years (post pubertal-stage IV Tanner), either sex 3. Patients are pancreatic insufficient (i.e. with a positive faecal elastase test, and requiring pancreatic enzyme supplementation) 4. No evidence of overt liver disease (not on ursodeoxycholic acid) |
Key exclusion criteria | 1. Patients already taking vitamin K supplementation 2. Patients with osteoporosis or osteopaenia and taking bisphosphonates 3. Patients with abnormally low vitamin D levels (less than 30 µg) 4. Patients on maintenance oral corticosteroids 5. Patients who are considered to have very sedentary lifestyle or follow a rigorous exercise training programme 6. Patients with overt liver disease 7. Patients who do not consent to participate 8. Patients with a life expectancy of less than 12 months 9. Patients who are non-compliant with maintenance therapies |
Date of first enrolment | 02/01/2007 |
Date of final enrolment | 09/02/2009 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Department of Respiratory Medicine
London
E2 9JX
United Kingdom
E2 9JX
United Kingdom
Sponsor information
Barts and the London NHS Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Research and Development Department
24 - 26 Walden Street
Whitechapel
London
E1 2AN
England
United Kingdom
Website | http://www.bartsandthelondon.org.uk/ |
---|---|
https://ror.org/00b31g692 |
Funders
Funder type
Government
Barts and the London NHS Trust (UK) - Internally funded from Nursing, Midwifering and Allied Health Profession research grant
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
27/04/2016: No publications found, verifying study status with principal investigator